Merck Sprints Toward Late 2020 Filing For Pneumococcal Vaccine V114
Company Is Catching Up With Pfizer’s Planned Q4 Submission Of 20vPnC
Merck’s 15-valent vaccine candidate was non-inferior to Pfizer’s Prevnar 13 in a Phase III study and provided superior protection against serotype 3, a frequent cause of invasive pneumococcal disease.
You may also be interested in...
The company still plans to file 20vPnC for US FDA approval by the end of 2020 after the pneumococcal vaccine was non-inferior to Prevnar and to Pneumovax on six additional serotypes in older patients.
The big drug maker will pay as much as $52 million to tap protein expression technology used to make proteins for developing a vaccine candidate.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.